Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 1
1986 1
1987 1
1988 1
1989 1
1990 1
1992 3
1993 7
1994 3
1995 2
1996 1
1997 2
1998 10
1999 6
2000 10
2001 10
2002 7
2003 10
2004 14
2005 16
2006 10
2007 14
2008 19
2009 24
2010 11
2011 16
2012 20
2013 29
2014 47
2015 55
2016 58
2017 39
2018 40
2019 72
2020 62
2021 60
2022 50
2023 41
2024 37
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

719 results

Results by year

Filters applied: . Clear all
Page 1
Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer.
Gomez-Rosas P, Nagy M, Spronk HMH, Russo L, Gamba S, Tartari CJ, Bolognini S, Ticozzi C, Schieppati F, Sarmiento R, De Braud F, Masci G, Tondini C, Petrelli F, Giuliani F, D'Alessio A, Santoro A, Gasparini G, Labianca R, Cate HT, Falanga A, Marchetti M; HYPERCAN Investigators. Gomez-Rosas P, et al. Among authors: de braud f. J Thromb Haemost. 2025 Jun;23(6):1908-1919. doi: 10.1016/j.jtha.2025.02.029. Epub 2025 Mar 6. J Thromb Haemost. 2025. PMID: 40056983
Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.
Gautschi O, Park K, Solomon BJ, Tomasini P, Loong HH, De Braud F, Goto K, Peterson P, Barker S, Liming K, Oxnard GR, Frimodt-Moller B, Drilon A. Gautschi O, et al. Among authors: de braud f. J Clin Oncol. 2025 May 20;43(15):1758-1764. doi: 10.1200/JCO-24-02076. Epub 2025 Feb 21. J Clin Oncol. 2025. PMID: 39983053 Free PMC article. Clinical Trial.
Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study.
De Micheli V, Agnelli L, Conca E, Rabsiun Aramburu VL, Baggi A, Vingiani A, Duca M, Perrone F, Tamborini E, Piccolo A, Lorenzini D, Busico A, Capone I, Niger M, Proto C, Vernieri C, Manoukian S, Gancitano G, Ferrario M, Franzini JM, De Braud F, Pruneri G, Jommi C. De Micheli V, et al. Among authors: de braud f. BMJ Open. 2025 May 16;15(5):e099134. doi: 10.1136/bmjopen-2025-099134. BMJ Open. 2025. PMID: 40379307 Free article.
A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma.
Pal SK, Bernard-Tessier A, Grell P, Gao X, Kotecha RR, Picus J, de Braud F, Takahashi S, Wong A, Suárez C, Otero JA, Kundamal N, Yang X, Sharaby S, Roy M, Barzaghi-Rinaudo P, Tannir NM. Pal SK, et al. Among authors: de braud f. Clin Cancer Res. 2025 May 15;31(10):1847-1855. doi: 10.1158/1078-0432.CCR-24-2618. Clin Cancer Res. 2025. PMID: 40043000 Free PMC article. Clinical Trial.
Effect of immuno-oncology on clinical and economic outcomes for a selection of cancers in Italy.
Canali B, Apolone G, Ascierto PA, De Braud F, Grossi F, Perrone F, Fiorentino F, Di Costanzo A, Candelora L, Patanè G, Zapparelli G, Mezzanotte C, Didoni G, Riccaboni M. Canali B, et al. Among authors: de braud f. Expert Rev Pharmacoecon Outcomes Res. 2025 May 8:1-11. doi: 10.1080/14737167.2025.2493130. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2025. PMID: 40329477 Free article.
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.
Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, Vernieri C; PALMARES-2 Study Group. Provenzano L, et al. Ann Oncol. 2025 Apr 8:S0923-7534(25)00134-6. doi: 10.1016/j.annonc.2025.03.023. Online ahead of print. Ann Oncol. 2025. PMID: 40204155 Free article.
Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST.
Pérol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C. Pérol M, et al. Among authors: de braud f. J Clin Oncol. 2025 Apr 3:JCO2500275. doi: 10.1200/JCO-25-00275. Online ahead of print. J Clin Oncol. 2025. PMID: 40179330
Assessment of cardiovascular, thromboembolic and cancer risk in patients eligible for treatment with Janus Kinase inhibitors: The JAK-ERA multidisciplinary consensus.
Dagna L, Alunno A, Farina N, Agnelli G, Borghi C, Caporali R, Costanzo A, Danese S, De Braud F, Sebastiani GD, Montecucco CM. Dagna L, et al. Among authors: de braud f. Eur J Intern Med. 2025 Apr;134:114-118. doi: 10.1016/j.ejim.2025.02.021. Epub 2025 Feb 20. Eur J Intern Med. 2025. PMID: 39979142
Reliability of core needle biopsy for HER2-low early-stage breast cancer.
Ciniselli CM, Verderio P, Duroni V, Baili P, Pizzamiglio S, de Braud FG, Folli S, Depretto C, Scaperrotta G, De Santis MC, Carnevale MG, De Marco C, Vingiani A, Pruneri G, Di Cosimo S. Ciniselli CM, et al. Among authors: de braud fg. Clin Transl Oncol. 2025 Mar 9. doi: 10.1007/s12094-025-03877-2. Online ahead of print. Clin Transl Oncol. 2025. PMID: 40057925
719 results